Platelet Activation in Patients with Unstable Angina

  • C. W. Hamm
  • W. Terres
  • W. Bleifeld
Conference paper


Unstable angina has become accepted as a clinical entity of coronary heart disease associated with a high risk of myocardial infarction and sudden cardiac death [1–4]. In recent years the pathogenetic mechanisms of unstable angina have been intensively investigated with the aim of better characterizing this high-risk group of patients. Evidence is now accumulating that platelet activation plays a major role in a complex cascade of events originating in arteriosclerotic plaque rupture and resulting in occlusive thrombus formation.


Unstable Angina Platelet Activation Plaque Rupture Platelet Factor Fuster Versus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Braunwald E (1989) Unstable angina, a classification. Circulation 80: 410–414PubMedCrossRefGoogle Scholar
  2. 2.
    Fowler NO (1971) “Preinfarctional” angina. Circulation 44, 5:755–758Google Scholar
  3. 3.
    Julian DG (1985) The natural history of unstable angina. In: Unstable angina. Current concepts and management. Schattauer, Stuttgart, pp 65–70Google Scholar
  4. 4.
    Wood P (1961) Acute and subacute coronary insufficiency. Br Med J 1779–1782Google Scholar
  5. 5.
    Born GVR (1985) Adenosine diphosphate as a mediator of platelet aggregation in vivo: an editorial view. Circulation 72, 4: 741–746PubMedCrossRefGoogle Scholar
  6. 6.
    Kaplan K, Broekman MJ, Chernoff A, Leszni GR, Drillings M (1979) Platelet a-granule proteins: studies on release and subcellular localization. Blood 53, 4: 604–618PubMedGoogle Scholar
  7. 7.
    Kohler N, Lipton A (1974) Platelets as a source of fibroblast growth-promoting activity. Exp Cell Res 87: 297–301PubMedCrossRefGoogle Scholar
  8. 8.
    Mills DC, Robb JA, Roberts GCK (1968) The release of nucleotides, 5-hydroxytryptomine and enzymes from human blood platelets during aggregation. J Physiol 195: 715–729PubMedGoogle Scholar
  9. 9.
    Needleman P, Moncada S, Bunting S, Vane JR, Hamberg M, Samuelsson B (1976) Identification of an enzyme in platelet microsomes which generates thromboxane AZ from prostaglandin endoperoxides. Nature 261: 558PubMedCrossRefGoogle Scholar
  10. 10.
    Libby P, Warner St, Salomon R, Birinyi L (1988) Production of platelet-derived growth factor-like mitogen by smooth-muscle cells from human atheroma. N Engl J Med 318, 23: 1493–1498PubMedCrossRefGoogle Scholar
  11. 11.
    Ross R, Glomset J, Kariya B, Harker L (1974) A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. Proc Natl Acad Sci USA 71, 4: 1207–1210PubMedCrossRefGoogle Scholar
  12. 12.
    Cazenave JP, Benveniste J, Mustard JF (1979) Aggregation of rabbit platelets by platelet-activating factor is independent of the release reaction and the arachidonate pathway and inhibited by membrane-active drugs. Lab Invest 41, 3: 275–285PubMedGoogle Scholar
  13. 13.
    Kaplan KL, Owen J (1981) Plasma levels of ß-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo. Blood 57, 2: 199–202PubMedGoogle Scholar
  14. 14.
    Moncada S, Gryglewski R, Bunting S, Vane JR (1976) An enzyme isolated from arteries transforms prostaglandin endo-peroxides to an unstable substance that inhibits platelet aggregation. Nature 263: 663PubMedCrossRefGoogle Scholar
  15. 15.
    Kinlough-Rathbone RL, Mustard JF, Perry DW, Dejana E, Cazenave JP, Packham MA, Harfenist EJ (1983) Factors influencing the deaggregation of human and rabbit platelets. Thromb Haemostas 49, 3: 162–167Google Scholar
  16. 16.
    Shattil SJ, Bennett JS (1980) Platelet and their membranes in hemostasis: physiology and pathophysiology. Ann Int Med 94: 108–118Google Scholar
  17. 17.
    Adams PH, Fuster V, Badimon L, Badimon JJ, Chesebro J (1987) Platelet/vessel wall interactions, rheologic factors and thrombogenic substrate in acute coronary syndromes: preventive strategies. Am J Cardiol 60:9G–16GPubMedCrossRefGoogle Scholar
  18. 18.
    Kramer C, Gerhardt HJ, Bleifeld W (1974) A model for closure of arterial vessels with special regard to the coronary arteries. Bas Res Cardiol 69: 585–596CrossRefGoogle Scholar
  19. 19.
    Wurzinger L, Blasberg P, Schmid-Schönbein H (1984) Rheologische Betrachtung der Abscheidungsthrombose. VASA 13: 305–310PubMedGoogle Scholar
  20. 20.
    Folts JD, Crowell EB, Rowe GG (1976) Platelet aggregation in partially obstructed vessels and its elimination with aspirin. Circulation 54: 365–370PubMedGoogle Scholar
  21. 21.
    Falk E (1985) Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Circulation 71: 699–708PubMedCrossRefGoogle Scholar
  22. 22.
    Davies MJ, Thomas AC (1985) Plaque fissuring — the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J 534: 363–373CrossRefGoogle Scholar
  23. 23.
    The TIMI Study Group (1985) The thrombolysis in myocardial infarction (TIMI) trial. Phase I findings. N Engl J Med 312: 932–936Google Scholar
  24. 24.
    Alison HW, Russell RO, Mantle JA, Kouchoukos N, Moraski RE, Rackley GH (1978) Coronary anatomy and arteriography in patients with unstable angina pectoris. Am J Cardiol 41: 204–209PubMedCrossRefGoogle Scholar
  25. 25.
    Neill WA, Ritzmann LW, Selden R (1977) The pathophysiologic basis of acute coronary insufficiency. Observations favoring the hypothesis of intermittent reversible coronary obstruction. Am Heart J 94: 439–444PubMedCrossRefGoogle Scholar
  26. 26.
    Ambrose JA, Hjemdahl-Monsen CE, Borrico S, Gorlin R, Fuster V (1988) Angiographie demonstration of a common link between unstable angina pectoris and non-Q-wave acute myocardial infarction. Am J Cardiol 61: 244–247PubMedCrossRefGoogle Scholar
  27. 27.
    Nellessen U, Hecker H, Danciu V, Specht S, Lichtlen PR, Borst HG (1986) Instabile Angina pectoris: Krankheitsbild and Verlauf neu überprüft. Z Kardiol 75: 707–718PubMedGoogle Scholar
  28. 28.
    Fuster V, Badimon L, Cohen M, Ambrose J, Badimon JJ, Chesebro J (1988) Insights into the pathogenesis of acute ischemic syndromes. Circulation 77: 1213–1220PubMedCrossRefGoogle Scholar
  29. 29.
    Vermylen J, Verstraete M, Fuster V (1986) Role of platelet activation and fibrin formation in thrombogenesis. J Am Coll Cardiol 8:2B–9BPubMedCrossRefGoogle Scholar
  30. 30.
    Terres W, Hamm CW, Kupper W, Bleifeld W (1988) Thrombozytenfunktion bei instabiler Angina pectoris. Dtsch Med Wschr 113: 1182–1186PubMedCrossRefGoogle Scholar
  31. 31.
    Chesebro JH, Fuster V (1987) The therapeutic challenge of plaque rupture: value of biochemical markers. J Am Coll Cardiol 10: 1005–1006CrossRefGoogle Scholar
  32. 32.
    Hamm CW, Bleifeld W (1988) Unstable angina; current concepts of medical management. Cardiovasc Drugs Therapy 2: 333–339CrossRefGoogle Scholar
  33. 33.
    Granström E, Diczfalusy U, Hamberg M, Hansson G, Malrosten C, Samuelsson B (1982) Thromboxane AZ: biosynthesis and effects on platelets. Prostaglandins and the Cardiovascular System 15–59Google Scholar
  34. 34.
    Patrono C, Ciabattoni G, Pugliese F, Perucci A, Blair IA, FitzGerald GA (1986) Estimated rate of thromboxane secretion into the circulation of normal humans. J Clin Invest 77: 1–6CrossRefGoogle Scholar
  35. 35.
    Roberts JL, Brash AR, Oates JA (1982) Metabolic fate of thromboxane A, and prostacyclin. Prostaglandins and the Cardiovascular System 213–223Google Scholar
  36. 36.
    Oates JA, FitzGerald GA, Branch RA, Jackson EK, Knapp HR, Roberts LJ (1988) Clinical implications of prostaglandin and thromboxane A, formation. New Engl J Med 319: 689–698PubMedCrossRefGoogle Scholar
  37. 37.
    Roberts JL, Sweetman BJ, Oates JA (1981) Metabolism of thromboxane B, in man. Identification of twenty urinary metabolites. J Biol Chem 256: 8384–8393PubMedGoogle Scholar
  38. 38.
    Nichols AB, Owen J, Grossman BA, Marcella JJ, Fleisher LN, Lee MML (1984) Effect of heparin bonding on catheter induced fibrin formation and platelet activation. Circulation 70: 843–850PubMedCrossRefGoogle Scholar
  39. 39.
    Sobel M, Salzman EW, Davies GC, Handin RI, Sweeney RN, Ploetz J, Kurland G (1981) Circulating platelet products in unstable angina pectoris. Circulation 63: 300–306PubMedCrossRefGoogle Scholar
  40. 40.
    De Boer AC, Turpie AG, Butt RW, Johnston RV, Genton E (1982) Platelet release and thromboxane synthesis in symptomatic coronary artery disease. Circulation 66: 327–333PubMedCrossRefGoogle Scholar
  41. 41.
    Hirsch PD, Hillis D, Campbell WB, Firth BG, Willerson JT (1981) Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. N Engl J Med 304: 685–691CrossRefGoogle Scholar
  42. 42.
    Mehta J, Mehta P, Feldman R, Horalek C (1984) Thromboxane release in coronary artery disease: spontaneous versus pacing-induced angina. Am Heart J 107: 286–292PubMedCrossRefGoogle Scholar
  43. 43.
    Neri Semen GG, Gensini GF, Abbate R, Prisco D, Rogasi PG, Laureano R, Casolo GC, Fantini F, Donato MD, Dabizzi RP (1985) Abnormal cardiocoronary thromboxane A, production in patients with unstable angina. Am Heart J 109: 732–738CrossRefGoogle Scholar
  44. 44.
    Lawson JA, Patrono C, Ciabattoni G, FitzGerald GA (1986) Long-lived enzymatic metabolites of thromboxane BZ in the human circulation. Analyt Biochem 155: 198–205PubMedCrossRefGoogle Scholar
  45. 45.
    Westlund P, Kumlin M, Nordenström A, Granström E (1986) Circulating and urinary thromboxane BZ metabolites in the rabbit: 11-dehydro-thromboxane B, as parameter of thromboxane production. Prostaglandins 31: 413–444PubMedCrossRefGoogle Scholar
  46. 46.
    Patrono C, Ciabattoni G, Patrignani P, Filabozzi P, Pinca E, Satta MA, Van Dorne D, Cinotti GA, Pugliese F, Pierucci A, Simonetti BM (1983) Evidence for a renal origin of urinary thromboxane B, in health and disease. Adv Prostaglandin, Thromboxane, Leukotriene Res 11: 493–498Google Scholar
  47. 47.
    FitzGerald GA, Pedersen AK, Patrono C (1983) Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation 67: 1174–1177PubMedCrossRefGoogle Scholar
  48. 48.
    Siess W, Lorenz R, Roth P, Weber PC (1982) Plasma catecholamines, platelet aggregation and associated thromboxane formation after physical exercise, smoking or norepinephrine infusion. Circulation 66: 44–48PubMedCrossRefGoogle Scholar
  49. 49.
    Gallino A, Haeberli A, Baur HR, Straub PW (1985) Fibrin formation and platelet aggregation in patients with severe coronary artery disease: relationship with the degree of myocardial ischemia. Circulation 72: 27–30PubMedCrossRefGoogle Scholar
  50. 50.
    Théroux P, Latour JG, Léger-Gauthier C, De Lara J (1987) Fibrinopeptide A and platelet factor levels in unstable angina pectoris. Circulation 5: 156–162CrossRefGoogle Scholar
  51. 51.
    Smitherman T, Milam M, Woo J, Willerson JT, Frenkel EP (1981) Elevated beta thromboglobulin in peripheral venous blood of patients with acute mocardial ischemia: Direct evidence for enhanced platelet reactivity in vivo. Am J Cardiot 48: 395–402CrossRefGoogle Scholar
  52. 52.
    Bugiardini R, Chierchia S, Crea F, Gallino A, Wild ST, Roskove A, Lenzi S, Maseri A (1984) Evaluation of the effects of catheter sampling for the study of platelet behavior in the pulmonary and coronary circulation. Am Heart J 108: 255–260PubMedCrossRefGoogle Scholar
  53. 53.
    Dusting GJ, Moncada S, Vane JR (1979) Prostaglandins, their intermediates and precursors: cardiovascular actions and regulatory roles in normal and abnormal circulatory systems. Prog Cardiovasc Dis 21: 405–430PubMedCrossRefGoogle Scholar
  54. 54.
    Weksler B (1984) Prostaglandins and vascular function. Circulation 70 (Suppl III): 63–71Google Scholar
  55. 55.
    Needelmann P, Kaley G (1978) Cardiac and coronary prostaglandin synthesis and function. N Engl J Med 298: 1122–1128CrossRefGoogle Scholar
  56. 56.
    Roy L, Knapp HR, Robertson RM, FitzGerald GA (1985) Endogenous biosynthesis of prostacyclin during cardiac catheterization and angiography in man. Circulation 71: 434–440PubMedCrossRefGoogle Scholar
  57. 57.
    Falardeau P, Oates A, Brash AR (1981) Quantitative analysis of two dinor urinary metabolites of prostaglandin I2. Analyt Biochem 115: 359–367PubMedCrossRefGoogle Scholar
  58. 58.
    Fischer S, Scherer B, Weber PC (1983) Prostacyclin metabolism in adults and neonates. Urinary profiles of 6-ketoprostaglandin F 1, and 2,3-dinor-6-ketoprostaglandin F 1 studied by gas chromatography — mass spectrometry. Biochim Biophys Acta 750: 127–133PubMedGoogle Scholar
  59. 59.
    FitzGerald GA, Smith B, Pedersen AK, Brash A (1984) Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. New Engl J Med 310: 1065–1068PubMedCrossRefGoogle Scholar
  60. 60.
    FitzGerald GA, Reilly IA, Pedersen AK (1985) The biochemical pharmacology of thromboxane synthetase inhibition in man. Circulation 72: 1194–1201PubMedCrossRefGoogle Scholar
  61. 61.
    Patrono C, Ciabattoni G, Patrignani P, Pugliese F, Filabozzi P, Catella F, Davi G, Forni L (1985) Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 72: 1177–1184PubMedCrossRefGoogle Scholar
  62. 62.
    Fitzgerald DJ, Roy L, Catella F, FitzGerald GA (1986) Platelet activation in unstable coronary disease. New Engl J Med 315: 983–989PubMedCrossRefGoogle Scholar
  63. 63.
    Hamm CW, Lorenz R, Bleifeld W, Kupper W, Wober W, Weber PC (1987) Biochemical evidence of platelet activation in patients with persistent unstable angina. J Am Coll Cardiol 10: 998–1004PubMedCrossRefGoogle Scholar
  64. 64.
    Gazes PC, Mobley EM, Faris HM, Duncan RC, Humphries GB (1973) Preinfarction (unstable) angina — a prospective study — ten year follow-up. Circulation 48: 331–337PubMedGoogle Scholar
  65. 65.
    Hook BG, Schumacher WA, Lee DL, Jolly StR, Lucchesi BR (1985) Experimental coronary artery thrombosis in the absence of thromboxane A2 synthesis: evidence for alternate pathways for coronary thrombosis. J Cardiovasc Pharmacol 7: 174–181PubMedCrossRefGoogle Scholar
  66. 66.
    Bunting S, Monada S, Vane JR (1983) The prostacyclin-thromboxane A2 balance: pathophysiological and therapeutic implications. British Med Bull 39: 271–276Google Scholar
  67. 67.
    Lorenz R, Hamm CW, Riesner H, Bleifeld W, Weber PC (1990) Urinary thromboxane excretion in patients presenting with acute severe chest pain. J Int MedGoogle Scholar
  68. 68.
    Cairns JA, Gent M, Singer J, Finnie KJ, Froggatt GM, Holder DA, Hablonsky G, Kostuk WJ, Melendez LJ, Myers MG, Sackett DL, Sealey JB, Tanser PH (1985) Aspirin, sulfinpyrazone, or both in unstable angina. N Engl J Med 313: 1369–1375PubMedCrossRefGoogle Scholar
  69. 69.
    Lewis HD, Davies JW, Archibald DG, Steinke WE, Smithermann TC, Doherty JE, Schnaper HW, Le Winter MM, Linares E, Pouget JM, Sabharwal SC, Chesler E, DeMots H (1983) Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. N Engl J Med 309: 396–403PubMedCrossRefGoogle Scholar
  70. 70.
    Théroux P, Ouimet H, McCans J, Latour JG, Joly P, Levy G, Pelletier E, Juneau M, Stasiak J, DeGuise P, Pelletier GB, Rinzler D, Waters DD (1988) Aspirin, heparin, or both to treat acute unstable angina. New Engl J Med 319: 1105–1111PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • C. W. Hamm
  • W. Terres
  • W. Bleifeld
    • 1
  1. 1.Abteilung für Kardiologie, Medizinische KlinikUniversitätskrankenhaus EppendorfHamburg 20West Germany

Personalised recommendations